Secukinumab Biosimilar(Mabtech)

司库奇尤单抗生物类似药(Mabtech)

Report date: 2024/09/29 17:48:40

Base Information

Drug NameSecukinumab Biosimilar(Mabtech)
Drug Alias NameCMAB015CMAB-015
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionInterleukin 17A inhibitors
TargetsInterleukin 17A
Therapy Area/IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesTaizhou Mabtech Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsPlaque psoriasisPsoriasisSpondylitis, Ankylosing
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A